Session 1091: Risk Assessment, Part 1

Cochair(s): P Hainaut, L Bubendorf
Date: Sun 10 February 2002, Time: 11:30 - 13:00
Location: CIS Auditorium

Oral Presentations

Time Number Title / Authors / Affiliations
11:30 270 Integration of Epstein-Barr virus into the host genome: a potential risk factor for the development of malignant lymphoma.
A Staratschek-Jox, J Bullerdiek, J Wolf
1Department of Internal Medicine I, University of Cologne, Germany, , 2Center for Human Genetics, University of Bremen, Germany
11:45 271 Late genetic effects of cancer therapy in cured ALL (acute lymphoblastic leukemia) and non-Hodgkins lymphoma patients as detected by DNA rearrangements
ML Camparoto, BC Brassesco, LPG D'Arce, SS Mello, LG Tone, GAS Passos, ET Sakamoto-Hojo
1Departamento de Genetica e, Faculdade de Medicina de Ribeirao Preto-USP, Campus de Ribeirao Preto, 2Departamento de Pediatria e Puericultura-HC, Faculdade de Medicina de Ribeirao Preto-USP, Campus de Ribeirao Preto, 3Faculdade de Odontologia de Ribeirao Preto-USP, Faculdade de Filosofia Ciencias e Letras de Ribeirao Preto-USP, Campus de Ribeirao Preto, 4Departamento de Biologia, Faculdade de Filosofia Ciencias e Letras de Ribeirao Preto-USP, Campus de Ribeirao Preto, S.P
12:00 272 Hormone replacement therapy (HRT) after breast cancer (BC).
A Gorins, M Espie, N Bedairia, F Perret, B Tournant, H Nowak, E Lucci, M Marty
1Centre des Maladies du Sein, Saint Louis Hospital, and Gustave Roussy Institut, , 2France
12:15 273 Hormone replacement therapy for African American women: missed opportunities for effective intervention.
WK Nicholson, AF Brown, J Gathe, K Grumbach, AE Washington, EJ Perez-Stable
Department of Gynecology and Obstetrics, The Johns Hopkins School of Medicine, Baltimore, San Francisco, CA
12:30 274 Possible role of ovarian epithelial inflammation in ovarian cancer.
RB Ness, C Cottreau
University of Pittsburgh, Pittsburgh, PA United States
12:45 275 Relevance of Helicobacter pylori virulence genes and interleukin-1 polymorphisms for the development of atrophy and gastric carcinoma
L van Doorn, C Figueiredo, C Machado, R Seruca, S Sousa, R Carvalho, C Caldas, W Quint, F Carneiro, M Sobrinho-Simões
1Delft Diagnostic Laboratory, Delft, The Netherlands, 2IPATIMUP, Porto, Portugal, 3Department of Oncology, University of Cambridge, Cambridge, United Kingdom, 4Faculty of Medicine, Porto, Portugal
13:00 276 Fluorescence endoscopy for the detection of dysplasia in ulcerative colitis using systemic or local 5-aminolevulinic acid sensitisation
E Endlicher, G Freunek, P Rümmele, J Schölmerich, R Knüchel, H Messmann
Internal Medicine I, Institute of Pathology, University of Regensburg, Germany

Poster Presentations

Number Title / Authors / Affiliations
277 Lung cancer risk assessment by breath acetonitrile
FB Bodrogi, PB Lirk, H Raifer, A Amann, JW Rieder
Department of Anesthesiology and Critical Care Medicine, Leopold-Franzens University of Innsbruck, Innsbruck, Tyrol Austria
278 Low frequency of colonic dysplasias in patients with longstanding IBD-colitis
T Ochsenkuhn, C Tillack, H Stepp, R Baumgartner, B Goeke, M Sackmann
1Department of Medicine II, Klinikum Grosshadern, Germany, 2Laser Research Institute, Klinikum Grosshadern, Germany
279 The significance of p53 codon 72 polymorphism for the development of cervical adenocarcinomas
S Andersson
Karolinska institutet, Huddinge Univers Hospital, Stockholm, Stockholm Sweden
280 The risk factor of hepatitis B virus associated hepatocellular carcinoma in pediatric patients
T Sogo, T Fujisawa, A Inui, N Shiki, H Komatsu, I Sekine
National Defense Medical College, Tokorozawa, Saitama Japan
281 Association between plasma MMP-9 activity and the outcome of breast cancer patients.
SM Ranuncolo, E Armanasco, C Cresta, EDBK Joffe, LI Puricelli
Research Area, Institute of Oncology "Angel H. Roffo", Buenos Aires, Buenos Aires Argentina
282 *Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 carriers.
P Ghadirian, MP Dubé, S Narod
1Epidemiology Research Unit, Research Centre, Hôtel-Dieu, University of Montreal, 2The Center for Research on Womens Health, University of Toronto, Canada
283 Distinct prevalence of CYP19 del3(TTTA)7 allele in premenopausal versus postmenopausal breast cancer patients
KP Hanson, EN Suspitsin, MY Grigoriev, AV Togo, ES Kuligina, EV Belogubova, KM Pozharisski, OL Chagunava, EP Sokolov, C Theillet, LM Berstein, EN Imyanitov
1N.N. Petrov Institute of Oncology, St.-Petersburg, Russia, 2Oleg L. Chagunava, Center of Mammology, St.-Petersburg, Russia, 3Evgeny P. Sokolov, Institute of Zoology, St.-Petersburg, Russia, 4Charles Theillet, Centre de Recherche en Cancerologie, Montpellier, France
284 Investigation of the effects of folic acid deficiency on colon carcinogenesis
GR Wasson, M Glynn, SR O'Reilly, M Kelvey-Martin, JJ Strain, DG Weir, JM Scott, CS Downes, M Nulty
1School of Biomedical Sciences, University of Ulster, Coleraine, Co. Londonderry, BT52 1SA, 2Department of Biochemistry and Clinical Medicine, Trinity College, Dublin, Ireland [ok]
285 *BRCA2 and genetic instability
Hutchison/MRC Cancer Research Centre, Cambridge, Cambridgeshire United Kingdom
286 Human papillomavirus prevalence, integration, and expression in head and neck cancers.
EM Smith, KF Summersgillb, JM Ritchiec, JR Ansond, MJ Lace, HT Hoffmane, JP Klussmannf, HP Dienesg, TH Haugen, LP Turek
1Department of Epidemiology, 2Department of Biostatistics, 3Department of; Veterans Affairs Medical Center, Iowa City, , 4Otolaryngology, 5Pathology; University of Iowa, Iowa City, , 6Department of Oral Pathology, and Department of Oto-Rhino-Laryngology, University of Pittsburgh, Head and Neck Surgery, , 7and Pathologyh, University of Cologne, Germany
287 PCR-ISH application potentiates the clinical and diagnostic assessment of cervical tissue.
L Vigni, UA Bianchi, G Carosi, M Lomini, S Pecorelli
1Institut Pasteur, Paris, France, 2Department of Obstetrics and Gynaecology, 3Department of Infectious and Tropical Diseases; University of Brescia, Spedali Civili of Brescia, Italy